{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:22:51Z","timestamp":1780701771611,"version":"3.54.1"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>One of the key clinical challenges of systemic sclerosis (SSc) is diversity in clinical presentation, organ involvement and disease progression. Antinuclear autoantibodies (ANA) are central to the diagnosis of SSc. ANA specificities associated with distinct clinical patterns of organ and skin involvement. Understanding of the molecular differences and pathogenesis of scleroderma has helped further inform clinical acumen. Here, we provide an update on ANA on clinical profiling, management and future direction of SSc.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>There has been further development in delineating clinical patterns in ANA, genetic susceptibility and antigen triggers predisposing to ANA subtypes. Sub-group analysis of recent clinical trials shows differing treatment responses to novel therapeutics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>ANA subtyping is likely to be firmly embedded into future classification systems. Beyond informing current management and monitoring of scleroderma patients, ANA subsets have implication on future research and clinical trial design.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000904","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T10:19:28Z","timestamp":1662718768000},"page":"302-310","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Scleroderma autoantibodies in guiding monitoring and treatment decisions"],"prefix":"10.1097","volume":"34","author":[{"given":"Shivani","family":"Shah","sequence":"first","affiliation":[{"name":"Royal Free Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[{"name":"Royal Free Hospital and University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/BOR.0000000000000550","article-title":"An update on autoantibodies in scleroderma","volume":"30","author":"Mecoli","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.41814","article-title":"Anticentromere antibody levels and isotypes and the development of systemic sclerosis","volume":"73","author":"van Leeuwen","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40674-016-0050-y","article-title":"Autoantibodies and their role in scleroderma clinical care","volume":"2","author":"Domsic","year":"2016","journal-title":"Curr Treat Options Rheum"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/diagnostics11050911","article-title":"Systemic sclerosis-associated pulmonary hypertension: spectrum and impact","volume":"11","author":"Naranjo","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"rky002","DOI":"10.1093\/rap\/rky002","article-title":"Distinctive clinical phenotype of anticentromere antibody-positive diffuse systemic sclerosis","volume":"2","author":"Caetano","year":"2018","journal-title":"Rheumatol Adv Pract"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"1759720X211032457","DOI":"10.1177\/1759720X211032457","article-title":"Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders","volume":"13","author":"Kuwana","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R9-20250526","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac047","article-title":"Autoantibody profiles associated with morbidity and mortality in scleroderma renal crisis","author":"Tsuji","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1136\/annrheumdis-2021-220402","article-title":"Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis","volume":"80","author":"Clark","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.semarthrit.2020.06.016","article-title":"Gastric antral vascular ectasia in systemic sclerosis: association with anti-RNA polymerase III and negative antinuclear antibodies","volume":"50","author":"Serling-Boyd","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3899\/jrheum.121087","article-title":"Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial","volume":"40","author":"Hung","year":"2013","journal-title":"J Rheumatol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1093\/rheumatology\/keab735","article-title":"Association between autoantibodies in systemic sclerosis and cancer in a national registry","volume":"61","author":"Hoa","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J Rheumatol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/acr.23291","article-title":"Association of fibrosing myopathy in systemic sclerosis and higher mortality","volume":"69","author":"Paik","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/diagnostics11061064","article-title":"Quantification of antifibrillarin (anti-U3 RNP) antibodies: a new insight for patients with systemic sclerosis","volume":"11","author":"Benyamine","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.autrev.2018.06.009","article-title":"Prevalence of auto-antibodies associated to pulmonary arterial hypertension in scleroderma \u2013 a review","volume":"17","author":"Nunes","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/art.42152","article-title":"Development of pulmonary hypertension in over one-third of patients with Th\/To antibody-positive scleroderma in long-term follow-up","volume":"74","author":"Suresh","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/rheumatology\/keab279","article-title":"Anti-RNPC-3 antibody predicts poor prognosis in patients with interstitial lung disease associated to systemic sclerosis","volume":"61","author":"Callejas-Moraga","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1097\/RHU.0000000000001676","article-title":"Anti-polymyositis\/scl antibodies in systemic sclerosis: clinical associations in a multicentric Spanish cohort and review of the literature","volume":"28","author":"Iniesta Arandia","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1093\/rheumatology\/keab152","article-title":"The clinical phenotype of systemic sclerosis patients with anti-PM\/Scl antibodies: results from the EUSTAR cohort","volume":"60","author":"Lazzaroni","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/rheumatology\/keab492","article-title":"Autoantibody profiles delineate distinct subsets of scleromyositis","volume":"61","author":"Leclair","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2169\/internalmedicine.5665-20","article-title":"Anti-PM\/Scl antibody-positive systemic sclerosis complicated by multiple organ involvement","volume":"60","author":"Shimizu","year":"2021","journal-title":"Intern Med"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/0961203308089442","article-title":"Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases","volume":"17","author":"Cavazzana","year":"2008","journal-title":"Lupus"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/ard.2007.073981","article-title":"Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multicentre case\u2013control study","volume":"67","author":"Rozman","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1097\/RHU.0000000000001395","article-title":"Anti-Ku antibody-related scleroderma-polymyositis overlap syndrome associated with hypothyroid myopathy","volume":"27","author":"Kadowaki","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/art.39432","article-title":"Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension","volume":"68","author":"Sobanski","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1756-185X.13908","article-title":"Clinical features of Japanese systemic sclerosis (SSc) patients negative for SSc-related autoantibodies: a single-center retrospective study","volume":"23","author":"Miyake","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1002\/art.39755","article-title":"Brief report: anti-eukaryotic initiation factor 2B autoantibodies are associated with interstitial lung disease in patients with systemic sclerosis","volume":"68","author":"Betteridge","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/rheumatology\/kex458","article-title":"Presence of antieukaryotic initiation factor-2B, anti-RuvBL1\/2 and antisynthetase antibodies in patients with antinuclear antibody negative systemic sclerosis","volume":"57","author":"Pauling","year":"2018","journal-title":"Rheumatology"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1684\/ejd.2019.3684","article-title":"A case of anti-RuvBL1\/2 antibody-positive systemic sclerosis overlapping with myositis","volume":"30","author":"Nomura","year":"2020","journal-title":"Eur J Dermatol"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3899\/jrheum.211139","article-title":"Three cases of systemic sclerosis within one family with different antibodies and clinical features","volume":"49","author":"Spierings","year":"2022","journal-title":"J Rheumatol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/art.22647","article-title":"Clinical, immunologic, and genetic features of familial systemic sclerosis","volume":"56","author":"Assassi","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/annrheumdis-2020-218558","article-title":"Genomic Risk Score impact on susceptibility to systemic sclerosis","volume":"80","author":"Bossini-Castillo","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/annrheumdis-2021-219884","article-title":"Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes","volume":"80","author":"Acosta-Herrera","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1073\/pnas.1906593116","article-title":"HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry","volume":"117","author":"Gourh","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1038\/s41467-019-12760-y","article-title":"GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways","volume":"10","author":"L\u00f3pez-Isac","year":"2019","journal-title":"Nat Commun"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3899\/jrheum.110071","article-title":"Antifibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis","volume":"38","author":"Sharif","year":"2011","journal-title":"J Rheumatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1073\/pnas.1906593116","article-title":"HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry","volume":"117","author":"Gourh","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/BOR.0000000000000834","article-title":"Insights into origins and specificities of autoantibodies in systemic sclerosis","volume":"33","author":"Tiniakou","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clim.2019.07.012","article-title":"A comprehensive analysis of antigen-specific antibody responses against human cytomegalovirus in patients with systemic sclerosis","volume":"207","author":"Efthymiou","year":"2019","journal-title":"Clin Immunol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00296-020-04643-z","article-title":"A study of antigen-specific anticytomegalovirus antibody reactivity in patients with systemic sclerosis and concomitant anti-Ro52 antibodies","volume":"40","author":"Gkoutzourelas","year":"2020","journal-title":"Rheumatol Int"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12016-021-08911-z","article-title":"Anti-Ro52 autoantibody is common in systemic autoimmune rheumatic diseases and correlating with worse outcome when associated with interstitial lung disease in systemic sclerosis and autoimmune myositis","volume":"63","author":"Chan","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/OARRR.S262428","article-title":"Association of silicone breast implants, breast cancer and anti-RNA polymerase III autoantibodies in systemic sclerosis: case-based review","volume":"12","author":"De Angelis","year":"2020","journal-title":"Open Access Rheumatol"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"25","DOI":"10.55563\/clinexprheumatol\/mg0paj","article-title":"Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis","volume":"39","author":"Lazzaroni","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13075-020-02360-3","article-title":"Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis","volume":"22","author":"Raschi","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/rheumatology\/keaa447","article-title":"Association of differentially expressed genes and autoantibody type in patients with systemic sclerosis","volume":"60","author":"Inamo","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"(SI)","key":"R48-20250526","doi-asserted-by":"crossref","first-page":"SI56","DOI":"10.1093\/rheumatology\/keab801","article-title":"Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening","volume":"61","author":"Gargani","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","article-title":"Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort","volume":"78","author":"Wu","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R51-20250526","first-page":"151","article-title":"Forced vital capacity in patients with systemic sclerosis associated pulmonary fibrosis: predictors of meaningful decline","volume":"59","author":"Svetlana","year":"2020","journal-title":"Rheumatology"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"102713","DOI":"10.1016\/j.autrev.2020.102713","article-title":"The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis","volume":"20","author":"Rubio-Rivas","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2397198320920422","article-title":"Mortality and morbidity in scleroderma renal crisis: a systematic literature review","volume":"6","author":"Kim","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.3389\/fimmu.2018.03112","article-title":"Intriguing relationships between cancer and systemic sclerosis: role of the immune system and other contributors","volume":"9","author":"Maria","year":"2018","journal-title":"Front Immunol"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"(suppl 10)","key":"R59-20250526","article-title":"Effect of anti-topoisomerase I antibody status on decline in lung function in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial [abstract]","volume":"71","author":"Mayes","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.41965","article-title":"Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and modified Rodnan Skin Thickness Score","volume":"74","author":"Kuwana","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/03009742.2017.1299793","article-title":"There is a need for new systemic sclerosis subset criteria. A content analytic approach","volume":"47","author":"Johnson","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"100141","DOI":"10.1016\/j.jtauto.2022.100141","article-title":"Autoantibodies in the disease criteria for systemic sclerosis: the need for specification for optimal application","volume":"5","author":"Damoiseaux","year":"2022","journal-title":"J Transl Autoimmun"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/08916934.2021.1907842","article-title":"Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests","volume":"54","author":"Alkema","year":"2021","journal-title":"Autoimmunity"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/RHU.0000000000000971","article-title":"Performance of anti-topoisomerase i antibody testing by multiple-bead, enzyme-linked immunosorbent assay and immunodiffusion in a university setting","volume":"26","author":"Homer","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"152052","DOI":"10.1016\/j.semarthrit.2022.152052","article-title":"False positive anti-topoisomerase I (Scl-70) antibody results in clinical practice: a case series from a scleroderma referral center","volume":"56","author":"Lam","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s10067-021-05586-x","article-title":"PM-Scl and Th\/To in systemic sclerosis: a comparison of different autoantibody assays","volume":"40","author":"Mecoli","year":"2021","journal-title":"Clin Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:19:14Z","timestamp":1748294354000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000904","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]}}}